Vandana Singh
·
July 25, 2025
Benzinga
Eli Lilly's donanemab gets CHMP backing for early Alzheimer's in select patients after trials show reduced disease progression and cognitive decline.
read more
July 30, 2025
July 23, 2025
Financial Times
May 14, 2025
Barchart
May 15, 2025
Fortune